Cosciens Biopharma Inc (CSCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 3,322 | 1,871 | 2,337 | 2,057 | 1,671 |
| Cost of Goods | 1,273 | 914 | 1,518 | 1,153 | 2,446 |
| Gross Profit | 2,049 | 957 | 819 | 904 | -775 |
| Operating Expenses | 7,679 | 8,164 | 5,092 | 2,871 | -2,132 |
| Operating Income | -5,357 | -6,293 | -3,755 | -1,814 | 1,803 |
| Interest Expense | 22 | 22 | 22 | 63 | 87 |
| Other Income | -270 | 448 | 1,881 | 64 | 252 |
| Pre-tax Income | -5,649 | -5,867 | -1,896 | -1,813 | 1,968 |
| Income Tax | 1,082 | -112 | -474 | -412 | -438 |
| Net Income Continuous | -6,731 | -5,755 | -1,422 | -1,401 | 2,406 |
| Net Income | $-6,731 | $-5,755 | $-1,422 | $-1,401 | $2,406 |
| EPS Basic Total Ops | -2.68 | -1.85 | -0.64 | -0.76 | 2.51 |
| EPS Basic Continuous Ops | -2.68 | -1.85 | -0.64 | -0.76 | 2.50 |
| EPS Diluted Total Ops | -2.68 | -1.85 | -0.64 | -0.76 | 2.51 |
| EPS Diluted Continuous Ops | -2.68 | -1.85 | -0.64 | -0.76 | 2.50 |
| EPS Diluted Before Non-Recurring Items | -2.15 | -1.85 | -0.64 | N/A | N/A |
| EBITDA(a) | $-5,782 | $-5,853 | $-3,378 | $-1,455 | $2,162 |